Kahn Swick & Foti, LLC and Former Louisiana Attorney General Notify XenoPort Shareholders of Class A
KSF is a law firm focused on securities class action litigation with offices in Louisiana and New York.   11:17 Jul 30, 2010

Competitive Technologies' Calmare(R) Pain Therapy Device Treating Patients at Commonwealth Pain Spec
FAIRFIELD, Conn., July 30, 2010 ( GLOBE NEWSWIRE)- Competitive Technologies, Inc. announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from c   07:26 Jul 30, 2010

Sunwin International Reports Financial Results for the Fiscal 2010 Year Ended April 30, 2010
AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For the Year Ended April 30, 2010 2009 Revenues $ 14,060,990 $ 22,209,912 Revenues- related party 431,969- Total Revenues $ 14,492,959 $ 22,209,912 Cost of revenues 11,931,027 17,129,87   05:57 Jul 30, 2010

Icagen to Report Second Quarter 2010 Results on August 10, 2010
These risk factors include risks as to the Company's lack of liquidity and substantial doubt about the Company's ability to continue as a " going concern;", the Company's ability to raise additional funding; the Company's history of net los   05:38 Jul 30, 2010

The Female Health Company Schedules Third Quarter Conference Call for August 6, 2010
About The Female Health Company The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® ( FC2), which is available in the U.S. and about 100 other countries around the world.   05:37 Jul 30, 2010

NicOx first half 2010 financial results
Key events of the first six months of 2010:- NicOx and Bausch+ Lomb signed a Worldwide Licensing Agreement for the glaucoma candidate NCX 116- The European Medicines Agency ( EMA) validated the Marketing Authorization Application ( MAA) for   23:07 Jul 29, 2010

Pacgen Reports Fiscal 2010 Financial Results
In addition, Dr. Yiu Chung Lee, Dr. Beverly Incledon, Mr. Joel Cheng and Mr. Gabriel Lam from Xphase were appointed to the Company's management team to assume the role of Chief Executive Officer ( " CEO"), Vice President, Research and Devel   22:07 Jul 29, 2010

Protein Found on Stem Cells Protects Against Immune Attack
The company's lead product, the endometrial regenerative cell ( ERC), is a " universal donor" stem cell being developed for critical limb ischemia.   16:17 Jul 29, 2010

Depomed to Announce Second Quarter 2010 Financial Results on August 5, 2010
About Depomed Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in   15:26 Jul 29, 2010

Novartis Vaccines Begins Shipment of Seasonal Influenza Vaccine Fluvirin(R) to U.S. Market to Help P
Novartis Vaccines plans to supply approximately 40 million doses of Fluvirin vaccine to support U.S. seasonal influenza vaccination in people 4 years of age and older CDC universally recommend annual seasonal flu vaccination for everyone 6   13:47 Jul 29, 2010

Acura Pharmaceuticals Reports Second Quarter 2010 Financial Results
The most significant of such factors include, but are not limited to, our ability and the ability of King ( to whom we have licensed our Aversion ( R) Technology for certain opioid analgesic products in the United States, Canada and Mexico)   13:26 Jul 29, 2010

TomoTherapy Announces Second Quarter Financial Results
TOMOTHERAPY INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( In thousands, except per share data) ( unaudited) Three Months Ended Six Months Ended June 30, June 30, 2010 2009 2010 2009 Revenue: Product $ 34,24   13:07 Jul 29, 2010

Insulet Reports Second Quarter 2010 Results
These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on the OmniPod System; Insulet's ability to increase customer orders and manufacturing volumes; adverse changes in general economi   13:07 Jul 29, 2010

Holzer Holzer & Fistel, LLC Announces That It Has Filed a Class Action Lawsuit on Behalf of Investor
Holzer Holzer & Fistel, LLC Michael I. Fistel, Jr., Esq. mfistel@ holzerlaw. com Marshall P. Dees, Esq. mdees@ holzerlaw. com ( 888) 508-6832 200 Ashford Center North, Suite 300 Atlanta, GA 30338   09:26 Jul 29, 2010

...

News Copyright © 2006 Interest!ALERT